BACKGROUND: Thrombin and the thrombin receptor have been implicated in the proliferation of vascular smooth muscle cells (VSMCs) observed after angioplasty and in atherosclerosis. Because thrombin receptor activation is an irreversible proteolytic event, the marked upregulation of the smooth muscle cell thrombin receptor after vascular injury may account for the maintained mitogenic activity of thrombin. The present study was designed to determine whether aggregating platelets stimulate thrombin receptor expression in cultured VSMCs and, if so, to identify the mediators. METHODS AND RESULTS: Thrombin receptor expression was assessed by Northern and Western blot analyses and functionally by measuring the release of 6-keto prostaglandin F1alpha. Platelet-derived products (PDPs) released by aggregating human platelets enhanced thrombin receptor mRNA levels in a time- and concentration-dependent manner, an effect that was potentiated by transient acidification of PDPs, which release bioactive transforming growth factor (TGF)-beta1, and that was slightly inhibited by ketanserin. Among several factors known to be released by aggregating platelets, only TGF-beta1, platelet-derived growth factorAB (PDGF(AB)), and serotonin mimicked the PDP effect. The level of membrane thrombin receptor protein was increased in TGF-beta1-treated VSMCs. Pretreatment of VSMCs with either acidified PDP, or TGF-beta1 increased the alpha-thrombin-stimulated release of 6-keto prostaglandin F1alpha. This effect was blunted by incubating acidified PDP with either a TGF-beta- or a PDGF-neutralizing antibody. CONCLUSIONS: Aggregating human platelets stimulate the expression of thrombin receptors in VSMCs through the release of TGF-beta1, PDGF(AB), and, to a lesser extent, serotonin. The upregulation of the thrombin receptor by products released by aggregating platelets may sustain the mitogenic activity of thrombin in the vascular wall at sites of injury.
BACKGROUND:Thrombin and the thrombin receptor have been implicated in the proliferation of vascular smooth muscle cells (VSMCs) observed after angioplasty and in atherosclerosis. Because thrombin receptor activation is an irreversible proteolytic event, the marked upregulation of the smooth muscle cell thrombin receptor after vascular injury may account for the maintained mitogenic activity of thrombin. The present study was designed to determine whether aggregating platelets stimulate thrombin receptor expression in cultured VSMCs and, if so, to identify the mediators. METHODS AND RESULTS:Thrombin receptor expression was assessed by Northern and Western blot analyses and functionally by measuring the release of 6-keto prostaglandin F1alpha. Platelet-derived products (PDPs) released by aggregating human platelets enhanced thrombin receptor mRNA levels in a time- and concentration-dependent manner, an effect that was potentiated by transient acidification of PDPs, which release bioactive transforming growth factor (TGF)-beta1, and that was slightly inhibited by ketanserin. Among several factors known to be released by aggregating platelets, only TGF-beta1, platelet-derived growth factorAB (PDGF(AB)), and serotonin mimicked the PDP effect. The level of membrane thrombin receptor protein was increased in TGF-beta1-treated VSMCs. Pretreatment of VSMCs with either acidified PDP, or TGF-beta1 increased the alpha-thrombin-stimulated release of 6-keto prostaglandin F1alpha. This effect was blunted by incubating acidified PDP with either a TGF-beta- or a PDGF-neutralizing antibody. CONCLUSIONS: Aggregating human platelets stimulate the expression of thrombin receptors in VSMCs through the release of TGF-beta1, PDGF(AB), and, to a lesser extent, serotonin. The upregulation of the thrombin receptor by products released by aggregating platelets may sustain the mitogenic activity of thrombin in the vascular wall at sites of injury.
Authors: Shannon M Jones; Adrien Mann; Kelsey Conrad; Keith Saum; David E Hall; Lisa M McKinney; Nathan Robbins; Joel Thompson; Abigail D Peairs; Eric Camerer; Katey J Rayner; Michael Tranter; Nigel Mackman; A Phillip Owens Journal: Arterioscler Thromb Vasc Biol Date: 2018-03-29 Impact factor: 8.311
Authors: J Graff; D Andries; M Elsner; D Westrup; S Bassus; N Franz; U Klinkhardt; S Harder Journal: Br J Clin Pharmacol Date: 2001-06 Impact factor: 4.335
Authors: David C J Howell; Robin H Johns; Joseph A Lasky; Bin Shan; Chris J Scotton; Geoffrey J Laurent; Rachel C Chambers Journal: Am J Pathol Date: 2005-05 Impact factor: 4.307
Authors: Jochen Graff; Ute Klinkhardt; Dagmar Westrup; Carl M Kirchmaier; Hans Klaus Breddin; Sebastian Harder Journal: Br J Clin Pharmacol Date: 2003-09 Impact factor: 4.335
Authors: Jasimuddin Ahamed; Nathalie Burg; Keiji Yoshinaga; Christin A Janczak; Daniel B Rifkin; Barry S Coller Journal: Blood Date: 2008-06-10 Impact factor: 22.113
Authors: Ingrid Brænne; Lingyao Zeng; Christina Willenborg; Vinicius Tragante; Thorsten Kessler; Cristen J Willer; Markku Laakso; Lars Wallentin; Paul W Franks; Veikko Salomaa; Abbas Dehghan; Thomas Meitinger; Nilesh J Samani; Folkert W Asselbergs; Jeanette Erdmann; Heribert Schunkert Journal: PLoS One Date: 2017-08-22 Impact factor: 3.240
Authors: Gerrit Kann; Junaid Owasil; Karina Kuczka; Annette Haberl; Timo Wolf; Pavel Khaykin; Sebastian Harder; Christoph Stephan; Nils von Hentig Journal: HIV AIDS (Auckl) Date: 2021-08-06